Mid
M
MLTXAI Stock Diagnostic Report
Needham raises MapLight Therapeutics stock price target on trial data
Needham has positively evaluated the clinical data results of Maplight Therapeutics and has raised its target price.
View Source Article ↗
AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
MLTX Analysis History (Last 30 Days)